Enhanced antitumor activity by combining an adenovirus harboring ING4 with cisplatin for hepatocarcinoma cells

Cancer Gene Therapy

Volumn 18, Issue 3, 2011, Pages 176-188

  Xie, Y ^a,b   Sheng, W ^a   Miao, J ^a   Xiang, J ^b   Yang, J ^a  

^a SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

adenoviral vector; cisplatin; enhanced antitumor activity; hepatocarcinoma; ING4

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CD34 ANTIGEN; CISPLATIN; FAS ANTIGEN; GROWTH INHIBITOR; INHIBITOR OF GROWTH 4 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENETIC VECTORS; HEK293 CELLS; HEP G2 CELLS; HOMEODOMAIN PROTEINS; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MUS; MUS MUSCULUS;

EID: 79951726719     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.67     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156. (Pubitemid 32911406)
2. Kamel IR, Kruskal JB, Raptopoulos V. Imaging for right lobe living donor liver transplantation. Semin Liver Dis 2001; 21: 271-282. (Pubitemid 32552256)
3. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817-823.
4. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001; 234: 63-70. (Pubitemid 32619336)
5. Poon RT, Fan ST. Resection prior to liver transplantation for hepatocellular carcinoma: a strategy of optimizing the role of resection and transplantation in cirrhotic patients with preserved liver function. Liver Transpl 2004; 10: 813-815.
6. Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002; 235: 466-486. (Pubitemid 34258345)
7. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430. (Pubitemid 32844200)
8. Shiseki M, Nagashima M, Pedeux RM, Kitahama-Shiseki M, Miura K, Okamura S et al. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res 2003; 63: 2373-2378. (Pubitemid 36605171)
9. He GH, Helbing CC, Wagner MJ, Sensen CW, Riabowol K. Phylogenetic analysis of the ING family of PHD finger proteins. Mol Biol Evol 2005; 22: 104-116. (Pubitemid 39628547)
10. Aasland R, Gibson TJ, Stewart AF. The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biochem Sci 1995; 20: 56-59.
11. Doyon Y, Cayrou C, Ullah M, Landry AJ, Cote V, Selleck W et al. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell 2006; 21: 51-64. (Pubitemid 43017848)
12. Zhang X, Wang KS, Wang ZQ, Xu LS, Wang QW, Chen F et al. Nuclear localization signal of ING4 plays a key role in its binding to p53. Biochem Biophys Res Commun 2005; 331: 1032-1038. (Pubitemid 40692464)
13. Garkavtsev I, Kozin SV, Chernova O, Xu L, Winkler F, Brown E et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004; 428: 328-332. (Pubitemid 38418804)
14. Gunduz M, Nagatsuka H, Demircan K, Gunduz E, Cengiz B, Ouchida M et al. Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene 2005; 356: 109-117. (Pubitemid 41175976)
15. Fang F, Luo LB, Tao YM, Wu F, Yang LY. Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2009; 18: 409-416.
16. Li J, Martinka M, Li G. Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis 2008; 29: 1373-1379.
17. Cai L, Li X, Zheng S, Wang Y, Li H, Yang J et al. Inhibitor of growth 4 is involved in melanomagenesis and induces growth suppression and apoptosis in melanoma cell line M14. Melanoma Res 2009; 19: 1-7.
18. Li M, Jin Y, Sun WJ, Yu Y, Bai J, Tong DD et al. Reduced expression and novel splice variants of ING4 in human gastric adenocarcinoma. J Pathol 2009; 219: 87-95.
19. Zhang X, Xu LS, Wang ZQ, Wang KS, Li N, Cheng ZH et al. ING4 induces G2/M cell cycle arrest and enhances the chemosensitivity to DNA-damage agents in HepG2 cells. FEBS Lett 2004; 570: 7-12. (Pubitemid 38900947)
20. Colla S, Tagliaferri S, Morandi F, Lunghi P, Donofrio G, Martorana D et al. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood 2007; 110: 4464-4475. (Pubitemid 351377813)
21. Xie Y, Zhang H, Sheng W, Xiang J, Ye Z, Yang J. Adenovirus-mediated ING4 expression suppresses lung carcinoma cell growth via induction of cell cycle alteration and apoptosis and inhibition of tumor invasion and angiogenesis. Cancer Lett 2008; 271: 105-116.
22. Xie YF, Sheng W, Xiang J, Zhang H, Ye Z, Yang J. Adenovirus-mediated ING4 expression suppresses pancreatic carcinoma cell growth via induction of cell-cycle alteration, apoptosis, and inhibition of tumor angiogenesis. Cancer Biother Radiopharm 2009; 24: 261-269.
23. Kim S, Chin K, Gray JW, Bishop JM. A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer, Proc Natl Acad Sci USA, 2004, 101, 16251-16256 (Pubitemid 39552831)
24. Unoki M, Shen JC, Zheng ZM, Harris CC. Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility. J Biol Chem 2006; 281: 34677-34686. (Pubitemid 46036673)
25. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573-584. (Pubitemid 47106628)
26. Rosenberg B, Vancamp L, Krigas T. Inhibition of Cell Division in Escherichia Coli by Electrolysis Products from a Platinum Electrode. Nature 1965; 205: 698-699.
27. Morton RP, Rugman F, Dorman EB, Stoney PJ, Wilson JA, McCormick M et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 1985; 15: 283-289. (Pubitemid 15240980)
28. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etopo-side. N Engl J Med 1987; 316: 1435-1440. (Pubitemid 17079090)
29. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61: 517-525. (Pubitemid 32128610)
30. Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic anti-tumor efficacy without increasing toxicity. Cancer Res 2001; 61: 5453-5460. (Pubitemid 32694926)
31. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995; 36: 169-180.
32. Dings RP, Yokoyama Y, Ramakrishnan S, Griffioen AW, Mayo KH. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res 2003; 63: 382-385. (Pubitemid 36152496)
33. Nozell S, Laver T, Moseley D, Nowoslawski L, De Vos M, Atkinson GP et al. The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes. Mol Cell Biol 2008; 28: 6632-6645.
34. Shen JC, Unoki M, Ythier D, Duperray A, Varticovski L, Kumamoto K et al. Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res 2007; 67: 2552-2558. (Pubitemid 46548940)
35. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 1999; 33: 29-55. (Pubitemid 30083118)
36. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-490. (Pubitemid 28391864)
37. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501. (Pubitemid 28391865)
38. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol 1998; 16: 395-419. (Pubitemid 28183370)
39. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodi-merizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619. (Pubitemid 23259742)
40. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
41. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
42. Kong C, Zhu Y, Sun C, Li Z, Sun Z, Zhang X et al. Inhibition of tumor angiogenesis during cisplatin chemotherapy for bladder cancer improves treatment outcome. Urology 2005; 65: 395-399. (Pubitemid 40248049)
43. Tan GH, Tian L, Wei YQ, Zhao X, Li J, Wu Y et al. Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities. Int J Cancer 2004; 112: 701-706. (Pubitemid 39425953)